-- Suzhou Ribo Life Science (HKG:6938) said it submitted a phase 2b clinical trial application to the European Medicines Agency for its core product Vortosiran for stroke prevention in atrial fibrillation, according to a Tuesday Hong Kong bourse filing.
Vortosiran targets factor XI to reduce clotting activity and may offer thromboembolic protection with lower bleeding risk, the filing said.